Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-63733657 in early Alzheimer's disease
NL-OMON52097Phase 2Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of posidinemab in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Primary endpoint: Integrated Alzheimer's Disease Rating Scale. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
posidinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON52097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52097.